| Autophagy induction by the 30-100kDa fraction of areca nut in both normal and malignant cells through reactive oxygen species. | |
| | |
MedLine Citation:
|
PMID: 20920876 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Areca nut (AN) is an addictive carcinogen used by about 200-600 million people worldwide. Some AN components are shown to induce apoptosis; however, we previously demonstrated that AN extract (ANE) and the 30-100kDa fraction of ANE (ANE 30-100K) induced autophagy-like responses, such as swollen cell morphology, empty cytoplasm, acidic vesicles, and LC3-II accumulation, in an oral cancer cell line, OECM-1. To further assess the responses of other cell types to ANE 30-100K, we used both normal and malignant cells as the targets of ANE 30-100K and found that normal oral fibroblasts (CMT415), peripheral blood lymphocytes (PBLs), Jurkat leukemia T cells, and esophageal carcinoma cells (CE81T/VGH) exhibited similar responses after ANE 30-100K challenge. ANE 30-100K drastically increased acidic vesicle-containing PBLs isolated from two independent donors (from 0.1% to 92.1% and 2.9% to 64.2%). Furthermore, both ANE- and ANE 30-100K-induced LC3-II accumulation in CMT415 and CE81T/VGH was further increased in the presence of the lysosomal protease inhibitors (pepstatin A, E64d, and leupeptin). On the other hand, ANE 30-100K also increased the level of intracellular reactive oxygen species (ROS), and the ROS scavengers, N-acetylcysteine (NAC) and Tiron, inhibited ANE 30-100K-induced cell death and LC3-II accumulation. Collectively, these results suggest the existence of an autophagy-inducing AN ingredient (AIAI) in ANE 30-100K, which renders ANE as an autophagic flux inducer through ROS in both normal and malignant cells. |
| | |
Authors:
|
Mei-Huei Lin; Wan-Fang Hsieh; Wei-Fan Chiang; Wen-Zhai Hong; Yu-Rung Hsu; Yon-Chi Cheng; Tai-Chi Chen; Kai-Cheng Hsu; Pin-Yan Lin; Pin-Yan Lina; Shyun-Yeu Liu; Young-Chau Liu |
Related Documents
:
|
16404156 - Transduced human copper chaperone for cu,zn-sod (pep-1-ccs) protects against neuronal c... 11678606 - On the mechanism of cr (vi)-induced carcinogenesis: dose dependence of uptake and cellu... 11597896 - Et-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of re... 11284726 - Hierarchies of atp-consuming processes: direct compared with indirect measurements, and... 3940186 - Oncogenic transformation of c3h10t1/2 mouse embryo cells by x-rays, hyperthermia, and c... 10954586 - Puralpha: a multifunctional single-stranded dna- and rna-binding protein. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Oral oncology Volume: 46 ISSN: 1368-8375 ISO Abbreviation: Oral Oncol. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-29 Completed Date: 2011-04-20 Revised Date: 2011-05-17 |
Medline Journal Info:
|
Nlm Unique ID: 9709118 Medline TA: Oral Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 822-8 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Biotechnology, Chia Nan University of Pharmacy, Tainan, Taiwan, ROC. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Areca
/
chemistry* Autophagy / drug effects* Blotting, Western Cell Line, Tumor Female Fibroblasts / drug effects, metabolism Humans Male Mouth Neoplasms / chemically induced* Oxidative Stress / drug effects Plant Extracts / pharmacology* Reactive Oxygen Species / metabolism* T-Lymphocytes / drug effects, metabolism Up-Regulation / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Plant Extracts; 0/Reactive Oxygen Species |
| Comments/Corrections | |
Erratum In:
|
Oral Oncol. 2011 Mar;47(3):228 Note: Lina, Pin-Yan [corrected to Lin, Pin-Yan] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Automatic microvolt T-wave alternans identification in relation to ECG interferences surviving prepr...
Next Document: Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinom...